American Association for Cancer Research (AACR)
The AACR recently held its 2026 conference from April 17-22, 2026. Read below to learn about MBC-related reports from this meeting.
- Breast Cancer Research Foundation: Artificial intelligence and innovative therapies were presented at AACR 2026 and may improve understanding and treatment of MBC (scroll to “Artificial Intelligence is Reshaping…” and “New Treatment Modalities…”)
American Society of Clinical Oncology (ASCO)
ASCO 2026 was held May 29-June 2, 2026. Click the links below to learn about new MBC research presented at this meeting.
- Susan G. Komen: Data from several clinical trials presented at ASCO 2026 supported FDA approvals later that year for new treatments for people with MBC
- Breastcancer.org: Promising results were presented for people with MBC and brain metastases and people receiving supportive care (scroll to “Stereotactic Radiation Before Surgery…” and “Mobile App Improves…”)
- Living Beyond Breast Cancer: An experimental drug called izalontamab brengitecan that targets two proteins may improve outcomes in people with triple-negative MBC (scroll to “New Kind of ADC…”)